Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/30/25
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation AerosolGlobeNewsWire • 10/29/25
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster HeadachesGlobeNewsWire • 10/27/25
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/23/25
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in FocusZacks Investment Research • 10/06/25
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?Zacks Investment Research • 10/02/25
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)GlobeNewsWire • 09/26/25
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps GrowingSeeking Alpha • 09/11/25
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable SuspensionGlobeNewsWire • 09/04/25
Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a BetZacks Investment Research • 09/01/25
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?Zacks Investment Research • 08/14/25
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/25
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in MexicoGlobeNewsWire • 08/05/25